Dovitinib, a multi-kinase inhibitor targeting FGFR, VEGFR, PDGFRβ, and c-Kit (stem cell factor receptor), has been investigated as a potential treatment for GBM, especially in recurrent cases [77,78]. Here, KDR is linked to glioblastoma.